Shenzhen Haiwang Bioengineering Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the content of this information disclosure is true, accurate, and complete, without false records, misleading statements, or significant omissions.
Special Reminder:
- The internal control audit report for the Company's 2025 financial report received a negative opinion. According to Article 9.8.1 (4) of the Shenzhen Stock Exchange Listing Rules (2026 Revision), the Company's stock will be subject to other risk warnings starting May 6, 2026.
- In accordance with Article 9.4.4 of the Shenzhen Stock Exchange Listing Rules, the Company must disclose relevant progress at least once a month.
I. Overview of Other Risk Warnings
Deloitte Touche Tohmatsu Certified Public Accountants LLP issued a negative opinion on the internal control audit report for the Company's 2025 financial year. According to Article 9.8.1 (4) of the Shenzhen Stock Exchange Listing Rules (2026 Revision), the Company's stock will be subject to other risk warnings starting May 6, 2026.